Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd has announced the release of its next-generation PromarkerD test system, a diagnostic tool designed to predict diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before symptoms appear. This advancement, presented at the American Diabetes Association’s Scientific Sessions, marks a significant step towards global commercialization and regulatory expansion, offering a simplified yet accurate method to identify at-risk individuals, thereby enabling early intervention and potentially reducing the progression to severe renal conditions.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services, particularly in the field of proteomics. The company is dedicated to improving quality of life through innovative tools that enhance disease treatment.
Average Trading Volume: 198,330
Technical Sentiment Signal: Sell
Current Market Cap: A$58.87M
For a thorough assessment of PIQ stock, go to TipRanks’ Stock Analysis page.